Why the study?
Does sirolimus therapy cause regression and hemodynamic improvement in fetuses with intrapericardial giant cardiac rhabdomyomas?
Does sirolimus therapy cause regression and hemodynamic improvement in fetuses with intrapericardial giant cardiac rhabdomyomas?
Sirolimus therapy may be an effective treatment for rapid regression and hemodynamic improvement of prenatally identified intrapericardial giant cardiac rhabdomyomas.
Answers are grounded in this paper and cite their sources.
Sirolimus may promote regression of rare fetal pericardial rhabdomyomas; leaves open questions on dosing, safety, and generalizability.
•Giant cardiac rhabdomyomas were identified on fetal echocardiography.•The rhabdomyomas were unusually located in the pericardial space.•Rapid regression and hemodynamic improvement were seen with sirolimus therapy.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: